These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1668237)

  • 1. Are increased ATP blood levels responsible for PGI2 release from endothelium?
    Salari PC; Marni A; Parisé M; Calvani AB; Spaggiari PG; Gaja G; Ferrero ME
    Int J Tissue React; 1991; 13(4):219-23. PubMed ID: 1668237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin release from endothelial cells, induced by defibrotide treatment, favours the function of grafted rat hearts and kidneys.
    Ferrero ME; Marni A; Salari PC; Spaggiari PG; Gaja G
    Int J Tissue React; 1991; 13(4):215-8. PubMed ID: 1821415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defibrotide, a stimulator of prostacyclin (PGI2) production, prevents the effects of ischaemic damage.
    Ferrero ME; Marni A; Rovati M; Aimini R; Salari PC; Gaja G
    Int J Tissue React; 1989; 11(4):179-84. PubMed ID: 2517498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiischaemic effect of defibrotide treatment in rat kidney.
    Corsi M; Parise M; Gaja G; Ferrero ME
    Drugs Exp Clin Res; 1993; 19(6):261-5. PubMed ID: 8013269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of defibrotide on prostacyclin release from isolated rabbit kidneys and protection from post-ischemic acute renal failure in vivo.
    Berti F; Rossoni G; Bianchi G; Alberico P; Tettamanti R; Calvani AB; Mantovani M; Prino G
    Eicosanoids; 1991; 4(4):209-15. PubMed ID: 1789997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of defibrotide in endothelial cell protection.
    Corsi M; Parise M; Gaja G; Ferrero ME
    Int J Tissue React; 1993; 15(4):157-61. PubMed ID: 8188455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion.
    Lefer AM; Aoki N; Mulloy D
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Mar; 341(3):246-50. PubMed ID: 2160617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin.
    Scalia R; Kochilas L; Campbell B; Lefer AM
    Methods Find Exp Clin Pharmacol; 1996 Dec; 18(10):669-76. PubMed ID: 9121223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial mechanisms of action of a prostacyclin enhancing agent in splanchnic artery occlusion shock.
    Aoki N; Siegfried M; Tsao P; Lento P; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):275-89. PubMed ID: 3175328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of defibrotide in protecting ischemic myocardium from early reperfusion damage.
    Thiemermann C; Löbel P; Schrör K
    Am J Cardiol; 1985 Dec; 56(15):978-82. PubMed ID: 3907318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostacyclin and the mechanism of action of defibrotide.
    Gryglewski RJ; Marcinkiewicz E; Radomski M; Swies J
    Eicosanoids; 1989; 2(3):163-7. PubMed ID: 2517030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis.
    Pasini FL; Frigerio C; Capecchi PL; Ceccatelli L; Messa GL; Franchi M; Di Perri T
    Semin Thromb Hemost; 1996; 22 Suppl 1():15-20. PubMed ID: 8807723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial protection by defibrotide--a new strategy for treatment of myocardial infarction?
    Schrör K; Ackermann G; Hohlfeld T; Löbel P; Ney P; Schröder H; Strobach H
    Z Kardiol; 1989; 78 Suppl 6():35-41. PubMed ID: 2559554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP and 2,3-diphosphoglycerate changes in the erythrocytes of hyperammonaemic sheep.
    Debski B; Ryńca J
    Acta Physiol Pol; 1985; 36(5-6):345-51. PubMed ID: 3837603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits.
    Löbel P; Schrör K
    Atherosclerosis; 1989 Nov; 80(1):69-79. PubMed ID: 2513813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial "stunning".
    Hohlfeld T; Strobach H; Schrör K
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):108-15. PubMed ID: 1708043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats.
    Ma XL; Porta R; Pescador R; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):667-74. PubMed ID: 1663194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart.
    Löbel P; Schrör K
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):125-30. PubMed ID: 3937058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.